874100-37-5

Basic information

• Product Name: Benzamide, N-[2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethoxy]-5-ethenyl-3,4-difluoro- 2-[(2-fluoro-4-iodophenyl)amino]-
• CAS NO: 874100-37-5
• Molecular Formula: C23H28F3IN2O3Si
• Molecular Weight: 592.472
• Mol File: 874100-37-5.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: Benzamide, N-[2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethoxy]-5-ethenyl-3,4-difluoro- 2-[(2-fluoro-4-iodophenyl)amino]-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzamide, N-[2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethoxy]-5-ethenyl-3,4-difluoro- 2-[(2-fluoro-4-iodophenyl)amino]-(874100-37-5)
• EPA Substance Registry System: Benzamide, N-[2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethoxy]-5-ethenyl-3,4-difluoro- 2-[(2-fluoro-4-iodophenyl)amino]-(874100-37-5)

Safety Data

• Hazardous Substances Data: 874100-37-5(Hazardous Substances Data)

Upstream product

• 203916-59-0 2,3,4-trifluoro-5-iodobenzoic acid 
• 848852-32-4 2,3,4-trifluoro-5-vinylbenzoic acid 
• 848852-33-5 3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-5-vinylbenzoic acid 
• 152361-26-7 O-(2-(tert-butyldimethylsilyloxy)ethyl)hydroxylamine 

Downstream Products

• 874100-39-7 3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-5-formyl-N-(2-hydroxyethoxy)benzamide 
• 874100-38-6 N-[2-(tert-butyldimethylsilanyloxy)-ethoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-5-formyl-benzamide 
• 848851-77-4 (E)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-N-(2-hydroxy-ethoxy)-5-[(2-hydroxy-2-methyl-propoxyimino)-methyl]-benzamide 
• 848859-49-4 (E)-3,4-difluoro-2-(2-fluoro-4-trimethylsilanylethynyl-phenylamino)-N-(2-hydroxy-ethoxy)-5-[(2-hydroxy-2-methylpropoxyimino)-methyl]-benzamide 

Relevant articles and documents

5-SUBSTITUTED-2-PHENYLAMINO-BENZAMIDE AS MEK INHIBITOR

An objective of the present invention is to provide compounds that exhibit strong MEK-inhibiting activity and are stable in vivo and soluble in water, which can be used as preventive or therapeutic agents for proliferative diseases. The compounds of the present invention and pharmaceutically acceptable salts thereof are represented by the following formula (1): [where R1, R2, R3, R4, and X are the same as defined in the present patent application].